Emerging Agents Successful When Combined With Present Treatments Of Acute Lymphoblastic Leukemia

Armen Hareyan's picture
Advertisement

Acute Lymphoblastic Leukemia

Agents such as Biogen Idec/Genentech/Roche's Rituxan, Genzyme/Berlex's Campath, and Hana Biosciences' Marqibo will be incorporated into the multidrug chemotherapy regimens currently used as first- line treatment for acute lymphoblastic leukemia (ALL).

According to the new report entitled Emerging Therapies Will Be Adjuncts in this Niche Market: An Acute Lymphoblastic Leukemia Study, the combination use of Rituxan and the standard chemotherapy regimen hyper-CVAD (a treatment regimen that includes Bristol-Myers Squibb's Cytoxan, Baxter/Shionogi Seiyaku's Endoxan, generics; Eli Lily's Oncovin, generics; Bedford Labs' Adriamycin, Pfizer's Ariblastine/Adriacin, generics; Merck's Decadron, generics; Stada Pharmaceuticals' Rheumatrex, generics; Pfizer's Cytosar-U/Aracytine, Nippon Shinyaku's Cylocide, generics; and prednisone) shows the most promise and achieves the highest overall clinical rating among the emerging therapies.

"Clinical data demonstrate that improved disease-free survival was achieved when Rituxan was added to hyper-CVAD in ALL patients" said Clair Gricks, Ph.D., analyst at Decision Resources. "Hemato-oncologists are extremely positive about incorporating Rituxan into their first-line chemotherapy regimens, particularly hyper-CVAD, and they anticipate its use in a significant proportion of their patients. Based on feedback from surveyed physicians, we assume that Rituxan's market share will increase as clinical data mature."

Advertisement

The low incidence and heterogeneous biology of ALL creates challenges from a drug-development perspective. Physicians say that they depend on research in other disease areas that have overlapping biological characteristics with ALL for new agents to investigate in this patient group. Rituxan is already well established in other indications.

About Emerging Therapies Will Be Adjuncts in this Niche Market: An Acute Lymphoblastic Leukemia Study

Emerging Therapies Will Be Adjuncts in this Niche Market: An Acute Lymphoblastic Leukemia Study covers the current and future state of the acute lymphoblastic leukemia drug market. The report includes the following:

-- More than 3,000 physician responses that define drug attributes that drive prescription now and in the future.

Advertisement